Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a two-dimensional gradient technique applicable in routine microbiology

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 167-172

  van belkum, Alex ^a   Halimi, Diane ^a   Bonetti, Eve Julie ^b   Renzi, Gesuele ^b   Cherkaoui, Abdessalam ^b   Sauvonnet, Véronique ^a   Martelin, Roland ^a   Durand, Géraldine ^a   Chatellier, Sonia ^a   Zambardi, Gilles ^a   Engelhardt, Anette ^a,c   Karlsson, Åsa ^a,c   Schrenzel, Jacques ^b  

^a BIOMÉRIEUX   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c AB Biodisk Research Laboratories   (Sweden)

Author keywords

Antibiotic resistance; Susceptibility testing; Two dimensional etest

Indexed keywords

COLISTIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TITRIMETRY; TWO DIMENSIONAL GRADIENT TECHNIQUE; DRUG EFFECTS; DRUG POTENTIATION; EVALUATION STUDY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 84928316845     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku342     Document Type: Article

References (18)

1. García-Vázquez E, Moral-Escudero E, Hernández-Torres A et al. What is the impact of a rapid diagnostic Etest in the treatment of patients with Gram-negative bacteraemia? Scand J Infect Dis 2013; 45: 623-8.
2. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978; 137: 122-30.
3. Berenbaum MC. Correlations between methods for measurement of synergy. J Infect Dis 1980; 142: 476-80.
4. Bonapace CR, Bosso JA, Friedrich LV et al. Comparison of methods of interpretation of checkerboard synergy testing. Diagn Microbiol Infect Dis 2002; 44: 363-6.
5. Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349-58.
6. Pankey GA, Ashcraft DS, Dornelles A. Comparison of 3 Etestw methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagn Microbiol Infect Dis 2013; 77: 220-6.
7. Sopirala MM, Mangino JE, Gebreyes WA et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 4678-83.
8. Ericson M, Bolmstrom A. Method and Device for Studying and Quantifying Interacting Effects of Substances on Biological Cells. US Patent 5639632, 1997.
9. Bolmstrom A, Engelhardt A, Vidh P et al. A novel gradient technique for combination testing: trimethoprim and sulphamethoxazole model. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract E-2042. American Society for Microbiology, Washington, DC, USA.
10. Bolmstrom A, Engelhardt A, Bylund L et al. Synergy testing of cefepime and tobramycin against Pseudomonas aeruginosa and Acinetobacter baumannii isolates from intensive care units and cystic fibrosis with a novel combination gradient. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract E-798. American Society for Microbiology, Washington, DC, USA.
11. Bolmstrom A, Bylund L, Karlsson A et al. Quantifying synergy between colistin and rifampicin against carbapenem resistant Acinetobacter with a novel combination gradient. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract E-797. American Society for Microbiology, Washington, DC, USA.
12. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983; 11: 427-33.
13. Li RC, Schentag JJ, Nix DE. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrob Agents Chemother 1993; 37: 523-31.
14. Sheng WH, Wang JT, Li SY et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011; 70: 380-6.
15. Marques MB, Brookings ES, Moser SA et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997; 41: 881-5.
16. Tan TY, Lim TP, Lee WH et al. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011; 55: 436-8.
17. Cai Y, Chai D, Wang R et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67: 1607-15.
18. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697-701.